Results 31 to 40 of about 279,219 (179)

Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents

open access: yesBlood Advances, 2019
: The combination of venetoclax with hypomethylating agents (VEN-HMAs) showed promising activity in newly diagnosed and relapsed/refractory (r/r) acute myeloid leukemia (AML).
Ibrahim Aldoss   +17 more
doaj   +1 more source

Micafungin as antifungal prophylaxis in non-transplanted haemotological patients. [PDF]

open access: yes, 2019
Fungal infections are a major cause of morbidity and mortality in the haematological patients. These infections are mainly due to Candida spp. and Aspergillus spp.
Bergua, J M   +8 more
core   +3 more sources

The Outcome of Antifungal Prophylaxis with Posaconazole in Patients with Acute Myeloid Leukemia: A Single-Center Study

open access: yesTurkish Journal of Hematology, 2018
Objective: Invasive fungal infections (IFIs) are a significant cause of morbidity and mortality among neutropenic patients undergoing chemotherapy for acute myeloid leukemia (AML) and stem cell transplantation.
Vildan Özkocaman   +9 more
doaj   +1 more source

Safety and Efficacy of Intermittent High-Dose Liposomal Amphotericin B Antifungal Prophylaxis in Haemato-Oncology: An Eight-Year Single-Centre Experience and Review of the Literature

open access: yesJournal of Fungi, 2020
Triazoles remain first-line agents for antifungal prophylaxis in high-risk haemato-oncology patients, but their use is increasingly contraindicated due to drug–drug interactions and additive toxicities with novel treatments. In this retrospective, single-
Jonathan Youngs   +8 more
doaj   +1 more source

Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals

open access: yesInternational Journal of Infectious Diseases, 2019
Objectives: Novel formulations (gastro-resistant tablet and intravenous solution) of posaconazole (POS) have been approved in prophylaxis and therapy of invasive fungal diseases (IFDs).
Sebastian M. Heimann   +7 more
doaj   +1 more source

Attribute importance ranking for antifungal prophylaxis.

open access: yes, 2012
Attribute importance ranking for antifungal prophylaxis.
Marie-Chantal Ethier (127692)   +10 more
core   +1 more source

Willingness-to-pay for antibacterial and antifungal prophylaxis*.

open access: yes, 2012
*Willingness-to-pay for each scenario (95% confidence interval). Antibacterial prophylaxis scenario consists of the following for chances of infection, death and side effects for prophylaxis versus no prophylaxis: 25%, 1% and 25% versus 50%, 2%, 15 ...
Marie-Chantal Ethier (127692)   +10 more
core   +1 more source

Antifungal prophylaxis in stem cell transplantation centers in Turkey Türkiye'deki kök hücre nakli merkezlerinde antifungal profilaksi [PDF]

open access: yes, 2020
Objective: This study aimed to determine the current state of antifungal prophylaxis in Turkish stem cell transplantation (SCT) centers. Materials and Methods: The were 38 active stem cell transplantation centers in Turkey, 28 of which were registered ...
Hamdi Akan
core  

Defeating Multidrug‐Resistant ESKAPEE Pathogens With Polymer Nanomaterials

open access: yesAdvanced Science, EarlyView.
Antimicrobial resistance, particularly among ESKAPEE pathogens, represents a major global health threat and drives the need for innovative treatments. Polymer‐based strategies offer promising alternatives to conventional antibiotics by overcoming resistance mechanisms.
Thu Ba Tô   +4 more
wiley   +1 more source

Value of antifungal prophylaxis with antifungal drugs against oropharyngeal candidiasis in cancer patients

open access: yes, 1994
This report focuses on the value of antifungal prophylaxis with antifungal drugs in preventing oropharyngeal candidiasis. Randomised trials comparing non-AIDS immunocompromised patients receiving or not an oral antifungal agent were reviewed ...
Meunier, Françoise   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy